Trading halted on CVTX.  Announce at market close of a licensing aggreement for newly approved imaging agent Lexiscan (Regadensen).  The aggreement calls for a payment of 185 million dollars for 50% of North American rights. 

 

Have never heard of the collaborator.  This is a pretty good piece of change to allow for continued development of their lead compound already approved for one indication (Ranexa).

 

There was no pop on approval, but I bet its going to get a pop on this news!

 

Kutz